SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Major Vendor (Details) - Vendors - item |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Dec. 31, 2025 |
|
| Research and development expenditures | Supplier Concentration Risk | |||||
| Concentration | |||||
| Number of major vendors | 1 | 3 | 3 | 3 | |
| Concentration Risk (as a percent) | 57.00% | 40.00% | 55.00% | 44.00% | |
| Accounts payable and accrued expense | Lender Concentration Risk [Member] | |||||
| Concentration | |||||
| Concentration Risk (as a percent) | 12.00% | 6.00% | |||
| X | ||||||||||
- Definition Number of vendors that accounted for a significant portion of research and development expenditures during the reporting period No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|